an attenuated form of live bacteria with a DNA adenine methylase (Dam) activity altered relative to the Dam activity of the wild-type, unaltered, pathogenic form of the live bacteria, with the alteration being in a manner which renders the live bacteria attenuated; and

a first heterologous nucleotide sequence operatively inserted in the live attenuated bacteria which first heterologous sequence expresses a heterologous antigen.

3. (Amended) The immunogenic composition of claim 1, further comprising:

a second heterologous nucleotide sequence wherein the Dam activity is altered by the second heterologous nucleotide sequence.

4. (Amended) The immunogenic composition of claim 3, wherein the first heterologous sequence is operatively inserted into a first plasmid and further wherein the second heterologous sequence is operatively inserted into a second plasmid.

5. (Canceled).

7. (Amended) The immunogenic composition of claim 1, wherein the live attenuated bacteria is altered relative to its wild-type form by a genetically engineered change in its DNA which change is a non-lethal, non-reverting mutation which renders the bacteria attenuated.

18. (Amended) The immunogenic composition of claim 1, wherein the heterologous antigen is an antigen of a microorganism which causes a sexually transmitted disease.

30. (New) The immunogenic composition of claim 1, wherein the heterologous antigen is a mammalian tumor antigen.

31. (New) The immunogenic composition of claim 1, wherein the first heterologous nucleotide sequence is in a eukaryotic expression system.